Download MendeleyA Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.
Inoyama, D., Awasthi, D., Capodagli, G.C., Tsotetsi, K., Sukheja, P., Zimmerman, M., Li, S.G., Jadhav, R., Russo, R., Wang, X., Grady, C., Richmann, T., Shrestha, R., Li, L., Ahn, Y.M., Ho Liang, H.P., Mina, M., Park, S., Perlin, D.S., Connell, N., Dartois, V., Alland, D., Neiditch, M.B., Kumar, P., Freundlich, J.S.(2020) Cell Chem Biol 27: 560
- PubMed: 32197094
- DOI: https://doi.org/10.1016/j.chembiol.2020.02.007
- Primary Citation of Related Structures:
6P9K, 6P9L, 6P9M - PubMed Abstract:
Published Mycobacterium tuberculosis β-ketoacyl-ACP synthase KasA inhibitors lack sufficient potency and/or pharmacokinetic properties. A structure-based approach was used to optimize existing KasA inhibitor DG167. This afforded indazole JSF-3285 with a 30-fold increase in mouse plasma exposure. Biochemical, genetic, and X-ray studies confirmed JSF-3285 targets KasA. JSF-3285 offers substantial activity in an acute mouse model of infection and in the corresponding chronic infection model, with efficacious reductions in colony-forming units at doses as low as 5 mg/kg once daily orally and improvement of the efficacy of front-line drugs isoniazid or rifampicin. JSF-3285 is a promising preclinical candidate for tuberculosis.
Organizational Affiliation:
Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA.
